RECTAL CANCER APPARENT COMPLETE RESPONSE (acr) AFTER LONG COURSE CHEMORADIOTHERAPY

Similar documents
Manchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases

CHRISTIE COLORECTAL CANCER MDT FOLLOW-UP GUIDELINES

Early Rectal Cancer Surgical options Organ Preservation? Chinna Reddy Colorectal Surgeon Western General, Edinburgh

RECTAL CANCER CLINICAL CASE PRESENTATION

Guideline for the Follow-up of Patients with Gynaecological Malignancies

Bladder Cancer Guidelines

ADJUVANT CHEMOTHERAPY...

Treatment of Locally Advanced Rectal Cancer: Current Concepts

Colorectal Cancer Pathway Clinical Subgroup Tuesday 4 th September pm 4 pm CTCCU Seminar Room UHSM

CT PET SCANNING for GIT Malignancies A clinician s perspective

Audit Report. Colorectal Cancer Quality Performance Indicators. Patients diagnosed April 2014 March Published: July 2016

Colorectal Cancer Quality Performance Indicators

Colorectal Cancer Comparative Audit Report

Prognostic factors in squamous cell anal cancers

Audit Report. Colorectal Cancer Quality Performance Indicators. Patients diagnosed April 2016 March Published: March 2018

Adjuvant Chemotherapy for Rectal Cancer: Are we making progress?

Guideline for the Management of Vulval Cancer

Rectal Cancer : Curative treatment without surgery

HEAD AND NECK CANCERS

Carcinoma del retto: Highlights

Rectal cancer management: a team sport The role of radiology and the multidisciplinary conference

PATHWAY MANAGEMENT OF METASTATIC SPINAL CORD COMPRESSION (MSCC) THE CHRISTIE, GREATER MANCHESTER & CHESHIRE

Meta analysis in Rectal Cancer

Colorectal Cancer. Nimalan Pathma-Nathan

Outcome of rectal cancer after radiotherapy with a long or short waiting period before surgery, a descriptive clinical study

Upper GI Malignancies Imaging Guidelines for the Management of Gastric, Oesophageal & Pancreatic Cancers 2012

Case Conference. Craig Morgenthal Department of Surgery Long Island College Hospital

SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM)

Rectal Cancer: Classic Hits

Treatment strategy of metastatic rectal cancer

COLORECTAL CANCER Quality Performance Indicators (QPI) Comparative Report

Preoperative adjuvant radiotherapy

PROCARE FINAL FEEDBACK

State of the art: Standard(s) of radio/chemotherapy for rectal cancer

Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer

Where are we at with organ preservation for rectal cancer? Simon Bach Queen Elizabeth Hospital Birmingham ACPGBI Edinburgh 2016

Colorectal Pathway Meeting minutes Wednesday 16 th July 2014, 2 pm 4 pm Nightingale Lecture Theatre, UHSM

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

CURRENT PRACTICE OF FOLLOW-UP MANAGEMENT AFTER POTENTIALLY CURATIVE RESECTION OF RECTAL CANCER

HEAD AND NECK CANCERS

Colorectal Pathway Board (Clinical Subgroup): Imaging Guidelines September 2015

IMAGING GUIDELINES - COLORECTAL CANCER

Role of MRI for Staging Rectal Cancer

COLORECTAL CANCER COMPARATIVE AUDIT REPORT SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT. Mr B.J. Mander SCAN Group Chair

LCA Lung Clinical Forum. 21 st October 2014

Radiotherapy for Rectal Cancer. Kevin Palumbo Adelaide Radiotherapy Centre

How can we facilitate cross-boundary working in Greater Manchester?

Guidelines for the Management of Bladder Cancer

CHEMO-RADIOTHERAPY FOR BLADDER CANCER. Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre

Causation Issues. Delay in Diagnosis of Cancer Cases. Prof Pat Price Imperial College London

The Role Of The Post-CRT MRI In Assessing Response

West Midlands Sarcoma Advisory Group

Role of Cancer Registries and Data Banking in Quality Control of Breast Cancer Care

Appendix 4 Urology Care Pathways

Improving services for upper GI (OG) cancer Application template (Version 2)

North of Scotland Cancer Network Clinical Management Guideline for Oropharyngeal Cancer

SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM)

SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM)

BOWEL CANCER. Causes of bowel cancer

Guideline for the Management of Patients Suitable for Immediate Breast Reconstruction

Head and Neck Cancer 2010 COMPARATIVE AUDIT REPORT

COSD & Source of Referral

Aneurin Bevan University Health Board Breast Cancer and Pregnancy Guideline

NHS BLOOD AND TRANSPLANT ORGAN DONATION AND TRANSPLANTATION DIRECTORATE LIVER ADVISORY GROUP UPDATE ON THE HCC DOWN-STAGING SERVICE EVALUATION

The 1 st Oesophago gastric Cancer Centers Meeting for The Anglia Cancer Network

Upper GI Cancer Quality Performance Indicators

OESOPHAGO-GASTRIC CANCER 2016

COLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer

Ovarian Cancer Quality Performance Indicators

COLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer

NATIONAL BOWEL CANCER AUDIT The feasibility of reporting Patient Reported Outcome Measures as part of a national colorectal cancer audit

North of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix

Staging Issues: Lung Cancer & Mesothelioma. Mick Peake Clinical Lead, NCIN Chair, Lung SSCRG

Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs Lung /chest wall sarcomas incl. pulmonary metastatectomy Version 2

COLON AND RECTAL CANCER

Clinical Audit Data: 01 October 2015 to 30 September West of Scotland Cancer Network. Gynaecological Cancer Managed Clinical Network

Colorectal Cancer Clinical Quality Performance Indicators

Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer

Merkel Cell Carcinoma UHB is a no smoking Trust

Navigators Lead the Way

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

Coversheet for Network Site Specific Group Agreed Documentation

PROCARE FINAL FEEDBACK Definitions

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

COLON AND RECTAL CANCER

Colorectal Cancer Dashboard

Audit Report. Cervical Cancer Quality Performance Indicators. Patients diagnosed October 2014 September Published: September 2016

Oncological Treatment of Colorectal & Anal Cancer

Using Cancer Registration and MDT Data to Provide Information on Recurrent and Metastatic Breast Cancer

Colorectal Cancer. Mark Chapman. MA MS FRCS EBSQ(coloproct) 21 st March 2018 Consultant Coloproctologist

The optimum time to assess complete clinical response (CR)

A06/S(HSS)b Ex-vivo partial nephrectomy service (Adult)

COLORECTAL CANCER COMPARATIVE REPORT

COLORECTAL CARCINOMA

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

West Midlands Sarcoma Advisory Group

The accuracy of the diagnostic pathway for staging of low-mid rectal tumours with endoscopic, MRI and Endorectal Ultrasound assessment.

SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM)

Current innovations in colorectal surgery

Transcription:

COLORECTAL CLINICAL SUBGROUP RECTAL CANCER APPARENT COMPLETE RESPONSE (acr) AFTER LONG COURSE CHEMORADIOTHERAPY Finalised by: Dr Simon Gollins Mr Andrew Renehan Dr Mark Saunders Mr Nigel Scott Dr Shabbir Susnerwala Dr Arthur Sun Myint Oncologist North Wales Cancer Treatment Centre Colorectal Surgeon Christie Hospital Manchester Oncologist Christie Hospital Manchester Colorectal Surgeon Royal Preston Hospital Oncologist Royal Preston Hospital Oncologist, Clatterbridge Hospital

Introduction Long course chemoradiotherapy (LCCRT) followed by an 8-12 week gap has become the dominant neo-adjuvant therapy for locally advanced and lower 1/3 rectal carcinoma. This has the capacity to downstage (shrink) rectal cancer prior to surgery to try and ensure that the circumferential resection margin is clear. An important consequence of this development is that approximately 20%of rectal cancers will respond extremely well to LCCRT and on clinical examination apparently disappear from the rectal lumen after chemotherapy - apparent Complete Response (acr). A single centre clinical series of patients with acr (Sao Paulo, Brazil) has shown that a third of rectal cancer patients with acr will still have residual cancer however, perhaps two thirds may have achieved a true pathological complete response (ypcr) resulting in a local cure and who are therefore are unlikely to benefit from surgical excision of the rectum Surgical excision of the lower 1/3 rectal cancer is associated with major illness (up to 5% mortality, 40% morbidity) and a permanent stoma in many patients. Therefore an unnecessary rectal excision in a patient, who might have achieved local cure by chemoradiotherapy alone, should ideally be avoided. However, balanced against this desire to avoid unnecessary resection - one third of patients with an apparent complete response still have a cancer. The surgical management of these latter patients still requires rectal excision. Therefore any policy of acr observation (watch and wait) must involve rigorous and regular patient re-assessment of the apparent Complete Response to successfully salvage those patients that still have residual cancer. In these circumstances the evidence from the single centre Brazilian study is that delayed rectal excision, after a period of watch and wait, is not associated with any survival disadvantage. This guideline aims to clarify important aspects of the management of the apparent complete response after long course chemoradiotherapy for lower third rectal cancer: timing and definition of what constitutes an apparent complete response acr role of the MDT in the management of apparent complete response acr an audit mechanism for registering the apparent complete response acr patient information required for an informed decision resection or watch and wait the framework of assessment if the patient opts for watch and wait 1) Timing and Definition of apparent Complete Response The evidence is that the longer the assessment of the rectal cancer is delayed after long course chemoradiotherapy, then the greater is the reduction in the tumour volume. The current UK consensus is that the optimal delay between completion of chemoradiotherapy and assessment of rectal cancer response is between 8 and 12 weeks (recent published long course chemoradiation papers from the UK plus survey of UK oncologists at recent national NCRI research meetings). Whereas earlier assessment may indicate whether a tumour is or is not responding by reducing in size after chemoradiotherapy the presence or absence of an apparent complete response is best judged 12 weeks after the completion of chemoradiotherapy.

The methodology of defining an apparent complete response is: clinical examination under anaesthetic - with palpation of the tumour site and endoscopic examination including biopsy of the residual scar. Plus: MRI scan of the rectum showing either no evident tumour mass compared to baseline assessment or a small amount of residual tissue which in the opinion of the MDT is most likely to represent residual scar tissue rather than tumour. 2) The Role of the MDT in apparent Complete Response (acr) The role of the MDT in the management of apparent Complete Response includes: the formal recognition of acr based on the presented results of clinical examination, biopsy and MRI imaging 12 weeks after the completion of long course chemoradiotherapy registration of the acr on the central audit database Christie Hospital Fax Form discussion of possible therapeutic options to be put to the patient, including both the usual option of surgical resection and option of waiting with close observation. if the patient opts for waiting and close observation the MDT will formally review the clinical and MRI follow up data on that patient at 3 monthly intervals for the first 12 months. 3) The Audit Mechanism for apparent Complete Response (acr) The Audit Mechanism for acr will be in the form of a centralized database hosted at the Christie Hospital. The registration form is enclosed and the date will be collected on a data base to allow a more detailed examination of this cohort of patients. The data will be available to all networks. 4) Patient Information after apparent Complete Response (acr) Not removing the rectum in a patient with acr, after long course chemoradiotherapy for rectal cancer, is a novel step. That it is reasonable to discuss this course of action with a patient, stems from the considerable disadvantages associated with surgery, especially for the patient who has no cancer in the removed rectum. A patient information leaflet has been developed (Appendix 1) - but this is not a substitute for careful documented clinician discussion of all the potential advantages and disadvantages of each course of action, with the patient. There is uncertainty as to what is the correct course of action after acr has been established. The patient and the family require full participation in the decision as to whether they wish to follow conventional practice and proceed immediately to surgery or to whether they wish to defer surgery until there is evidence of residual cancer in the rectum.

5) Follow up after apparent Complete Response (acr) It is essential that the patient who opts for watch and wait in the setting of acr is subjected to careful and structured follow up. The components of follow up for the patient with acr in the first 12 months should be: 3 monthly EUA/ Endoscopy and site biopsy and / MRI scan; this is for the first 12 months after recognizing acr with programmed MDT 3 monthly review of follow up investigations for the first 12 months. after 12 months of negative follow up 3-monthly follow-up out patient appointments (with CEA) for the first 2 years with MRI scans at 12, 18 and 24 months and an EUA if any abnormality is seen or felt. if recurrent rectal cancer is discovered during follow up of acr the patient should be systemically restaged and offered surgical resection, if this is appropriate after anaesthetic assessment. [The outcome in any case at 24 months should be faxed to the Data Centre].

REGISTRATION: RECTAL CANCER and COMPLETE RESPONSE (CR) AFTER LONG COURSE CHEMORADIOTHERAPY (CRT) Fax Form to 0161 446 8148 Christie Hospital Today s DATE nhs no dob MDT Trust Cancer Diagnosed DATE Consultant / / / / Eligibility: YES NO Has the patient had a long course of CRT for the treatment of rectal cancer? Pre Chemo- Radiotherapy staging YES NO Discussed at the MDT? Initial stage of the tumour? T... N... Post Chemo-Radiotherapy imaging: YES NO Discussed at the MDT? CT: - Any distant disease? MRI: Good response but not radiological CR? MRI: Radiological CR? Post Chemo-Radiotherapy Clinical Examination: YES NO No palpable disease on EUA? No visible disease on Endoscopy? Negative Biopsies Complete Clinical Response? COMMENTS Decision - post MDT and informed patient discussion YES NO Radical Surgical Resection Close follow-up* Was formal consent documented for close FU? Other Decision COMMENTS: * We recommend 3-monthly follow-up out patient appointments (with CEA / endoscopy) for the first 2 years with MRI scans at 3, 6, 9, 12, 18 and 24 months and an EUA if any abnormality is seen or felt. Fax Form to 0161 446 8148 Christie Hospital